Company / Shareholders' Equity
Syndax Pharmaceuticals Inc Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$64.6M
FY2025
5-year range
$31.6M / $554.2M
FY2021-FY2025
Trend
-77.6%
vs FY2024
Sector context
#180 of 213
Health Care
What the data says
Syndax Pharmaceuticals Inc's shareholders' equity of $65M is lower than 85% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$252M in FY2017 to $554M in FY2023.
Based on SEC 10-K filings.
$65M in FY2025 with a 5-year CAGR of +4.0%.
Declined from $554M to $65M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -48.3%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 213This company $64.6M Sector average $2.5B
▼
-97.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 77.6% year-over-year.
- Ranks #180 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $64.6M | -77.6% |
| FY2024 | $288.1M | -48.0% |
| FY2023 | $554.2M | +18.6% |
| FY2022 | $467.4M | +1379.3% |
| FY2021 | $31.6M | -40.4% |
| FY2020 | $53.0M | -49.1% |
| FY2019 | $104.3M | +24.0% |
| FY2018 | $84.1M | +133.3% |
| FY2017 | -$252.4M | -65.4% |
| FY2016 | -$152.6M | +39.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026